secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2025-02-07T23:59:59+00:00
Accession:  0001628280-25-004313
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead appoints Sarepta CEO Douglas Ingram as director
---------------------------------------------------------

- Douglas Ingram appointed to Arrowhead board effective Feb 6, 2025, per Investor Rights Agreement with Sarepta.
- Ingram is President and CEO of Sarepta, with which Arrowhead has a collaboration agreement from Nov 2024.
- He receives standard non-employee director compensation plus sign-on RSUs of $771,200 vesting over 3 years.
- Ingram is not independent under Nasdaq rules due to the Sarepta collaboration and stock purchase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828025004313/0001628280-25-004313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828025004313/arwr-20250207.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-004313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer